Abstract
bThe current standard method for diagnosis of celiac disease (CD) is an
adequate small-bowel biopsy (usually obtained through upper gastrointestinal tract
endoscopy) showing characteristic histopathological changes, followed by a
therapeutic response to a gluten free diet. Commercially available IgA tissue trassglutaminase
antibody (TTG) screening tests have been developed with variable sensitivities and
specificities. The use of high titer cutoff values than currently recommended should improve
the specificity of the test and its positive predictive value.
Objectives. To evaluate the significance of high TTG titers in the diagnosis of CD.
Methods. One hundred sixteen patients with signs and symptoms suggestive of CD had
undergone TTG testings (IgA &IgG class) and small-bowel biopsies while 50 healthy
volunteers without family history of CD, were sent for TTG testings only. Ten patients
excluded from the study because their TTG values and small-bowel biopsies were negative.
Results. Ninety eight of 106 zpatients demonstrated positive biopsy results. Seventy two of
106 patients had IgA TTG levels of >100U/ml, with 70 of 72 exhibiting positive biopsy
Results. Twenty two of 28 patients with IgA TTG values >18-100U/ml exhibited positive
biopsy results. Six patients with negative IgA TTG levels of ≤18 U/ml had positive biopsies
and positive IgG TTG levels (>18 U/ml).Two volunteers had positive IgA TTG levels
(>18U/ml).The sensitivity and specificity of IgA TTG were 94.3% and 96% respectively
while the sensitivity of duodenal biopsy was 92.6%(8 symptomatic patients had negative
small-bowel biopsy while their IgA TTG values were positive).
Conclusions. Symptomatic patients with high titer TTG levels >100 U/ml can be treated as
CD without small-bowel biopsy and a negative biopsy does not exclude CD
adequate small-bowel biopsy (usually obtained through upper gastrointestinal tract
endoscopy) showing characteristic histopathological changes, followed by a
therapeutic response to a gluten free diet. Commercially available IgA tissue trassglutaminase
antibody (TTG) screening tests have been developed with variable sensitivities and
specificities. The use of high titer cutoff values than currently recommended should improve
the specificity of the test and its positive predictive value.
Objectives. To evaluate the significance of high TTG titers in the diagnosis of CD.
Methods. One hundred sixteen patients with signs and symptoms suggestive of CD had
undergone TTG testings (IgA &IgG class) and small-bowel biopsies while 50 healthy
volunteers without family history of CD, were sent for TTG testings only. Ten patients
excluded from the study because their TTG values and small-bowel biopsies were negative.
Results. Ninety eight of 106 zpatients demonstrated positive biopsy results. Seventy two of
106 patients had IgA TTG levels of >100U/ml, with 70 of 72 exhibiting positive biopsy
Results. Twenty two of 28 patients with IgA TTG values >18-100U/ml exhibited positive
biopsy results. Six patients with negative IgA TTG levels of ≤18 U/ml had positive biopsies
and positive IgG TTG levels (>18 U/ml).Two volunteers had positive IgA TTG levels
(>18U/ml).The sensitivity and specificity of IgA TTG were 94.3% and 96% respectively
while the sensitivity of duodenal biopsy was 92.6%(8 symptomatic patients had negative
small-bowel biopsy while their IgA TTG values were positive).
Conclusions. Symptomatic patients with high titer TTG levels >100 U/ml can be treated as
CD without small-bowel biopsy and a negative biopsy does not exclude CD